Evgen Pharma PLC Result of AGM (8329G)
21 Julio 2023 - 6:03AM
UK Regulatory
TIDMEVG
RNS Number : 8329G
Evgen Pharma PLC
21 July 2023
Evgen Pharma plc
("Evgen" or the "Company")
Result of AGM and Investor Presentation
21 July 2023 - Evgen Pharma plc (AIM: EVG), a clinical stage
drug development company developing sulforaphane-based medicines,
held its AGM yesterday, 20 July 2023, where all resolutions were
passed. The AGM voting results are available on the Company's
website here .
Following the completion of the AGM, Dr Huw Jones, CEO and
Richard Moulson, CFO held a virtual presentation and Q&A on the
InvestorMeet platform. The recording of this presentation is
available to view here .
-Ends-
Enquiries:
Evgen Pharma plc
Dr Huw Jones, CEO
Dr Helen Kuhlman, CBO +44 1625 466591
FinnCap (Nominated Advisor and Broker)
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane/Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris / Adam evgen@instinctif.com
Loudon
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. With respect to areas outside of oncology and
inflammation, Evgen signed an out-licensing deal with JuvLife, the
dietary products and functional foods division of Juvenescence Ltd,
for the development of a naturally-sourced sulforaphane nutritional
health supplement, stabilised using Evgen's Sulforadex(R)
technology. More recently Evgen completed an out-licensing
transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum
disorder. The deal, if successful, will generate milestone payments
of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGEAFXFAEEDEFA
(END) Dow Jones Newswires
July 21, 2023 07:03 ET (11:03 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De May 2023 a May 2024